Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing medicines for autoimmune and inflammatory diseases. Founded in 2021, the company focuses on creating internally discovered product candidates designed to target disease pathology and induce deep and durable remission in patients with unmet needs. Its lead product candidate, OD-001, is currently in Phase 2a clinical trials for the treatment of ulcerative colitis, with studies evaluating its use in combination with vedolizumab.

Summarised from the company's own disclosures

Industry Biotechnology Homepage investors.odysseytx.com
Sector Healthcare IR page investors.odysseytx.com
Tags
autoimmune diseases, inflammatory diseases, ulcerative colitis, clinical-stage, drug discovery, OD-001
Press page —

Metrics

Valuation  
Market cap —
Market cap (USD) —
P/E —
PEG —
P/BV —
P/S —
P/OCF —
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE —
ROI —
ROIC —
Profit margin —
Growth  
Revenue growing —
Profits growing —
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable —
Margin expanding —
Buying back stock —
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 19
Quality score —
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure Q3 2026 Q2 2026 Q1 2026
Assets 438.1M 483.85M 229.07M
Net profit -53.059M -52.788M -38.262M
Free cash flow -42.046M -34.694M -41.183M

Figure Q3 2026 Q2 2026 Q1 2026
Share price 22.22 18.71 —
P/FCF -6.33 -6.46 —

Filed figures

Figure Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 443,000 0.00
↳ YoY growth -100.0%
Lease liabilities (USD) — 27.1M
Cash and deposits (USD) 62.3M 41.7M
Intangible assets (USD) — 262,000
Right-of-use assets (USD) — 18.8M
Reported Jun 17, 2026 Jun 17, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Additional analyses from the Phase 2a induction period for OD-001 further strengthen clinical proof of concept in ulcerative colitis

Completed IND-enabling studies for OD-002, a first-in-class oral SLC15A4 inhibitor

$387 million in cash, cash equivalents and marketable securities as of September 30, 2026, expected to fund operations into the second half of 2028

BOSTON, November 4, 2026 (GLOBE NEWSWIRE) - Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology, today reported financial results for the third quarter ended September 30, 2026, and provided an update on recent progress and anticipated milestones.

October 20, 2026

PDF Version

Correlation between clinical efficacy and changes in inflammatory biomarkers, mucosal transcriptomic signatures, and histologic disease activity strengthens the previously shown clinical proof of concept for OD-001

Favorable tolerability profile and oral administration underscore the potential of OD-001 as a monotherapy and backbone for combination regimens in inflammatory bowel disease

Company to host conference call and webcast at 8:00 a.m. EDT

BOSTON, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology, today announced results from the completed induction period of its Phase 2a clinical trial evaluating OD-001, an oral, selective RIPK2 scaffolding inhibitor, in patients with moderate-to-severe ulcerative colitis (UC). The results were presented earlier today at United European Gastroenterology (UEG) Week in Barcelona, Spain, and will be discussed alongside additional analyses during a conference call and webcast to be hosted by Odyssey.

The completed OD-001 induction analysis comprises all 56 efficacy-evaluable patients. The high correlation between treatment outcomes and changes in inflammatory biomarkers, mucosal transcriptomic signatures, and histologic disease activity strengthens the previously established clinical proof of concept for OD-001 and provides biological evidence consistent with RIPK2 scaffolding inhibition. Combined with Phase 1 pharmacology data, these findings support 20 mg twice daily (BID) as the projected lowest maximally efficacious dose.

“These new analyses provide compelling evidence of pharmacologic activity at 20 mg BID, including clinical efficacy in patients with severe endoscopic disease and improvements across markers of intestinal and systemic inflammation,” said Gary D. Glick, Ph.D., founder and chief executive officer of Odyssey Therapeutics. “Transcriptomic findings that align with clinical activity and are consistent with RIPK2 scaffolding inhibition reinforce the mechanistic rationale for this approach in inflammatory bowel disease, strengthen our confidence in the treatment activity of OD-001, and support its continued clinical development.”

Key highlights from the induction period data

  • **Induction (Week 12) efficacy:**OD-001 met the trial’s primary endpoint of change from baseline in modified Mayo score at the end of induction at Week 12 (mean reduction of 2.4 points across the evaluable population; p<0.001). At this time point, clinical remission, clinical response, and symptomatic remission were 27%, 61%, and 49%, respectively, in the pooled 20 mg BID group (n=41) and 20%, 40%, and 27%, respectively, at 10 mg BID (n=15).

  • Improvement in validated biomarkers of intestinal and systemic inflammation: In patients treated with 20 mg BID, fecal calprotectin trended lower, hsCRP and circulating neutrophils were significantly decreased, and serum albumin significantly increased—all changes consistent with reduced intestinal and systemic inflammation. The reduction in neutrophils, a RIPK2-expressing cell type implicated in IBD pathogenesis, provides additional mechanistic support.

  • Rapid onset and deepening symptomatic benefit: Symptomatic remission at 20 mg BID reached 21% at Week 2, increasing throughout the induction period with no plateau observed through Week 12.

  • Comparable efficacy across prior treatment exposure: After 12 weeks of treatment with OD-001, clinical remission at 20 mg BID was 29% in advanced therapy-naïve (n=28) and 23% in advanced therapy-experienced (n=13) patients.

  • Clinical activity in patients with most severe endoscopic disease: Clinical remission at Week 12 for patients taking OD-001 at 20 mg BID was 16% in patients with a Mayo Endoscopic Score (MES) of 3 (n=19).

Transcriptomic analyses reinforce OD-001 treatment activity

  • On-target activity indicative of RIPK2 inhibition: Exploratory analyses of paired colonic biopsies from baseline and Week 12 showed reductions in RIPK2-responsive and downstream inflammatory gene signatures, including IL-23, TNF/NF-κB, TL1A, AP-1 and T-cell-associated pathways, supporting the proposed mechanism of action.

  • Modulation of fibrosis-associated and epithelial gene signatures: Reductions in fibrosis-associated signatures and increased expression of genes linked to epithelial homeostasis and mucosal healing aligned with clinical outcomes.

  • Distinct pharmacology relative to approved mechanisms: Exploratory patient-level comparisons with published datasets of approved therapies suggest OD-001 modulates RIPK2-associated pathways beyond general mucosal improvement achieved with other agents, supporting a differentiated mechanism of action and pharmacodynamic profile.

Safety and tolerability

OD-001 was generally well tolerated during the 12-week induction period, with no serious adverse events, serious infections, treatment-related discontinuations, or treatment-emergent liver function abnormalities. As previously reported, three adverse events in the 20 mg BID group were considered drug-related (two fevers and one headache). One Grade 3 anemia event in the 10 mg BID group occurred in a patient with pre-existing anemia, was considered unrelated to treatment, and resolved with iron supplementation without discontinuing OD-001.

Phase 2a clinical trial overview

The Phase 2a trial (NCT06850727) evaluated the efficacy, safety and tolerability of oral OD-001 in patients with moderate-to-severe ulcerative colitis using an open-label, dose-ranging design. The 12-week induction period included 10 mg and 20 mg BID dosing, with change from baseline in the three-component modified Mayo score as the primary endpoint. This open-label trial had no concurrent placebo control, and the data remain subject to change until database lock.

OD-001 advancing into Phase 2b monotherapy and Phase 2a combination trials

Odyssey plans to advance OD-001 into a randomized, placebo-controlled Phase 2b monotherapy trial and a randomized, active-controlled Phase 2a trial evaluating OD-001 plus vedolizumab versus vedolizumab plus placebo. Both studies will be double-blind, with topline induction results expected in the second half of 2027.

Conference call and webcast

Odyssey will host a conference call and webcast today at 8:00 a.m. EDT to discuss the completed Phase 2a induction results, including additional analyses beyond those presented at UEG. The live webcast and accompanying presentation will be available through the Investors section of Odyssey Therapeutics’ website at www.odysseytx.com. A replay will be available following the event.

About Odyssey Therapeutics

Odyssey Therapeutics is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that are designed to precisely target disease pathology. Since its founding in 2021, Odyssey has built a portfolio of internally discovered and developed medicines with its first program advancing through multiple clinical milestones. Odyssey’s portfolio leverages the scientific expertise of its team of experienced drug hunters and a comprehensive suite of tools to efficiently advance product candidates that the Company believes have the potential to induce deep and durable remission for patients across several inflammatory diseases with unmet need.

October 12, 2026

PDF Version

Topline induction results expected in the second half of 2027

BOSTON, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology, today announced that it will present the design of a randomized, double-blind Phase 2a trial evaluating OD-001 in combination with vedolizumab in patients with moderate-to-severe ulcerative colitis (UC) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting, taking place October 9-14, in Nashville, Tennessee.

The trial is designed to evaluate a differentiated combination strategy targeting complementary mechanisms of intestinal inflammation: OD-001 inhibits upstream RIPK2-mediated innate immune activation, while vedolizumab limits adaptive immune cell trafficking to the gut. By targeting innate immunity upstream of contemporary therapeutic targets, OD-001 is well positioned as a potential backbone for combination therapy. Building on previously reported Phase 2a proof-of-concept results for OD-001 monotherapy, the trial represents the first clinical evaluation of a combination approach targeting both innate and adaptive immunity in UC.

The trial is expected to enroll up to 146 patients globally and evaluate OD-001 in combination with vedolizumab during a 12-week induction period, followed by maintenance with OD-001 monotherapy through Week 52. Odyssey expects to provide topline induction results from this trial in the second half of 2027.

The poster presentation details are as follows:

Title: A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study Evaluating the Efficacy, Safety, and Pharmacokinetics of OD-001, a RIPK2 Scaffolding Inhibitor, in Combination With Vedolizumab in Moderate-to-Severe Ulcerative Colitis Presenter: Bruce Sands, M.D., M.S., Dr. Burrill B. Crohn Professor of Medicine and Chief, Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai Poster Number: 5698 Date and Time: Tuesday, October 13 from 10:30 a.m. – 4:00 p.m. CDT Room: Exhibit Halls A-D

About Odyssey Therapeutics Odyssey Therapeutics is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that are designed to precisely target disease pathology. Since its founding in 2021, Odyssey has built a portfolio of internally discovered and developed medicines with its first program advancing through multiple clinical milestones. Odyssey’s portfolio leverages the scientific expertise of its team of experienced drug hunters and a comprehensive suite of tools to efficiently advance product candidates that the Company believes have the potential to induce deep and durable remission for patients across several inflammatory diseases with unmet need.

Prompts

Odyssey Therapeutics, Inc. (ticker ODTX), listed in United States.

ETFs Holding Odyssey Therapeutics, Inc.

ETF Weight in ETF Shares Market value As of
MSSM 0.01% 3,353 $ 82.216K Aug 31, 2026
AVSC 0.01% 10,455 $ 202.409K Nov 16, 2026